Related Articles
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma
Expression of angiogenic growth factors VEGF, bFGF and ANG1 in colon cancer after bevacizumab treatment in vitro: A potential self-regulating mechanism
TCEB2 confers resistance to VEGF‑targeted therapy in ovarian cancer
Antitumor effects of bevacizumab in combination with fluoropyrimidine drugs on human oral squamous cell carcinoma